ZyVersa Therapeutics, Inc. ZVSA
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -99.25%
- 1 year
- -99.26%
- Market cap
- 8.10K
- EPS (ttm)
- -2.79
- Shares out
- 2.34M
- Forward P/E
- -0.24
- YTD return
- -99.25%
- 1-year return
- -99.26%
- Volume
- 77.96K
- Avg volume
- 8.93K
- Open
- 0.0455
- Previous close
- 0.001
- Day's range
- 0.0415 – 0.05
- 52-week range
- 0.001 – 0.30
- Beta
- 0.64
- Price target
- 20.00 (+1999900.0%)
- Earnings date
- Aug 9, 2024
1M -0.0790 (-98.75%)
Key statistics
- Enterprise value
- 1.04M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.54M
- Total cash
- 119.49K
- Total debt
- 0
- Return on equity
- -152.23%
- Short % of float
- 4.24%
- 50-day average
- 1.52
- 200-day average
- 3.80
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -2.73.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -5.80 | -2.43 | +3.37 | +58.10% |
| Aug 9, 2024 | Jun 1, 2024 | -5.20 | -3.31 | +1.89 | +36.35% |
| Aug 9, 2024 | Jun 1, 2024 | -5.20 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -3.70 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -3.70 | -4.53 | -0.83 | -22.43% |
| Mar 26, 2024 | Dec 1, 2023 | -2.14 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zyversa.com
News
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update 
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update 
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 65.4% – Still a Buy? 
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results 
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes 
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression 
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression 
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones 
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress 
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
Your note
Sign in to keep a note on ZVSA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.11% | 2,566 | 3.00K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 433 | 506 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 1 | Sep 29, 2024 |
| Royal Bank of Canada | 0.00% | 52 | 60 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 8 | 9 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 1 | 1 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.21% | 4,950 | 5.79K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 1,614 | 1.89K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 50 | 58 | Sep 29, 2024 |